Jasper Therapeutics has assembled an exceptional management team of experienced biopharma industry veterans. With this leadership, we are well positioned to achieve our vision of revolutionizing hematopoietic cell transplantation with safer conditioning regimens.
William Lis has been our independent Director since October 2018. He has 28 years of biopharmaceutical experience. He is the Executive Chairman, and interim CEO of Jasper Therapeutics, Inc where he led the company’s 2019 Series A financing. Previously, Mr. Lis served as Chief Executive Officer and a Director of Portola Pharmaceuticals, Inc. from 2008 until 2018 after serving as Chief Operating Officer. Under his leadership, Portola successfully grew from a discovery-stage company to a fully integrated research and development and commercial organization, and independently discovered and developed Andexxa® and Bevyxxa® through commercial launch, and advanced cerdulatinib into clinical development. He led corporate partnerships and private and public financings including an initial public offering in 2013. The company grew into a multi-billion valuation company during his tenure. Portola was acquired by Alexion Pharmaceuticals in 2020. Mr. Lis held executive positions at Scios, Inc. (a Johnson & Johnson company) where he last served as Sr. Vice President of Business Development and New Product Development, having led efforts for the in-licensing, development and pre-commercial launch for Xarelto®; He also held positions of increasing responsibility at Millennium Pharmaceuticals, Inc. (previously COR Therapeutics, Inc.) and Rhone Poulenc Rorer in sales, marketing, medical affairs and business development. He was involved in the U.S. commercial launch of several products, including Integrilin®, Lovenox® and Rilutek®. Mr. Lis served as a member of the Bio Board of Directors for Emerging Companies and is currently an independent Director of Eidos Therapeutics, Inc. and Zai Laboratories, Inc. Mr. Lis holds a B.S. from the University of Maryland.
Dr. Heller joined Jasper Therapeutics in August 2020 as Executive Vice President, Research and Development. Prior to that, he was Chief Medical Officer at NextCure, Inc., a biotechnology company developing immunotherapy-based biologics for cancer and other diseases. Before that, he was Vice President and head of antibody clinical development at Incyte, coordinating immunotherapy clinical development strategies for multiple antibody programs. He joined Incyte from AstraZeneca, where he was Senior Medical Director, overseeing global medicines development in oncology. Dr. Heller began his biopharma industry experience at Bristol Myers Squibb, where he led early development programs and was responsible for authoring and managing first-in-human clinical trials. His most recent position at BMS was Global Lead for Oncology Search and Evaluation, where he was responsible for leading a team matrix across disciplines during due diligence activities and preparing recommendations for possible acquisitions. Dr. Heller is currently Adjunct Professor of Medicine at Yale School of Medicine. Dr. Heller received a Bachelor’s degree in molecular biophysics and biochemistry from Yale University and a medical degree from George Washington University. He trained in pediatrics and pediatric hematology/oncology at Memorial Sloan Kettering Cancer Center. Following his fellowship, Dr. Heller joined the faculty of the Rockefeller University as Instructor and subsequently Chief Clinical Scholar of Clinical Investigation.
Mr. Mahal joined Jasper Therapeutics as Chief Financial and Business Officer from Portola Pharmaceuticals, where he worked for 11 years and held a number of positions of increasing leadership, most recently as Vice President, Business Development and Vice President, Strategic Marketing. He led the successful execution of multiple business development partnerships for Andexxa®, Bevyxxa® and cerdulatinib. He also played a key role in the company’s equity financings, including its initial public offering and multiple royalty transactions. Earlier in his career, he was Director, Business and New Product Development, at Johnson & Johnson on the Xarelto® development and strategic marketing team. He started his career in the drug development laboratories at COR Therapeutics.
Dr. Zoltowski joined Jasper Therapeutics in April 2020 as Senior Vice President, Regulatory Affairs and Quality. She has more than 25 years of experience in the pharmaceutical industry and has held positions of increasing responsibility, including contracting opportunities in regulatory affairs, quality and nonclinical toxicology, at Roche, Actelion, Portola Pharmaceuticals, Hyperion/Horizon and Ascendis Pharma. Her regulatory and management experience spans many therapeutic areas and includes successful submissions and negotiations with regulatory authorities in the United States, EU and Asia with both large and small molecule investigative products and drug-device combination products. She received a Doctor of Veterinary Medicine from the University of Pennsylvania and holds an active license in veterinary medicine in California.
Dr. Prohaska co-founded Jasper Therapeutics in 2019 and served as founding Chief Executive Officer before the appointment of Bill Lis. She is a Stanford University-trained scientist in immunology and stem cell biology with over 25 years of experience in preclinical and early clinical research in immunology, hematopoiesis, oncology and leading monoclonal antibody (mAb) development from discovery through early clinical stage. As Associate Director for Translational Programs at the Stanford Institute for Stem Cell Biology and Regenerative Medicine, and Program Director for JSP191/AMG191 development for the Division of Blood and Marrow transplant, she managed CMC, toxicology, regulatory, preclinical and clinical operations for anti-CD47 and JSP191 drug development programs at Stanford University. Prior to founding Jasper, she served as Associate Director for CMC overseeing clinical manufacturing of FSI-5F9 (now magrolimab) at Forty Seven Inc.
Ms. Hurt joined Jasper Therapeutics as Vice President of Clinical Operations in 2020. In this position, she is responsible for the leadership, strategic planning, oversight and execution of clinical programs. She has nearly 30 years of clinical trial experience. Most recently, she served as Vice President of Clinical Operations at Denali Therapeutics where she built the Clinical Operations function, which included Clinical Data Management and Clinical Outsourcing. She and her team were accountable for all activities related to execution and management of clinical studies and programs. Prior to that, she led Clinical Operations at Bavarian Nordic, XenoPort, Perlegen Sciences and Amgen. Ms. Hurt earned an M.P.H. and a B.S. from San Jose State University.
Dr. Di Noto joined Jasper Therapeutics in 2020 as Vice President, Technical Operations. He has extensive industry experience in process development, process scale-up, technology transfer, cGMP manufacturing, and regulatory submissions for biologic drugs. Before joining Jasper, he was at Portola Pharmaceuticals where he worked for five years as the Head of Drug Substance manufacturing, overseeing the Andexxa® program. As a member of the Technical Operation Senior Leadership Team, Dr. Di Noto played a vital role in building a robust manufacturing program, developing a global contract manufacturing network strategy, and achieving successful approval of a second-generation version of Andexxa, both in the United States and Europe. Before joining Portola, Dr. Di Noto worked at Alexion Pharmaceuticals where he developed processes for many of its lead candidate drugs both in early and late stages of development. Prior to that, he worked at Amgen. Dr. Di Noto started his career at the National Institutes of Health where he was a Research Fellow at the National Heart, Lung and Blood Institute).
Dr. Pang joined Jasper Therapeutics in 2020 from Stanford University where she was an Instructor in the Division of Blood and Marrow Transplantation. A physician-scientist with more than 20 years of experience conducting translational research in hematology/oncology and hematopoietic stem cell biology and transplantation, she was the lead scientist in the preclinical drug development of an anti-CD117 antibody at Stanford. She was the lead author on the proof-of-concept studies showing that an anti-CD117 antibody therapy targets disease-initiating human hematopoietic (blood cell-forming) stem cells in myelodysplastic syndrome (MDS). She has authored numerous publications on the characterization of hematopoietic stem and progenitor cell behavior in hematopoietic malignancies, including MDS and acute myeloid leukemia (AML), and in hematopoietic stem cell transplantation.